|1.||Tatsch, K: 4 articles (05/2012 - 02/2000)|
|2.||Tatsch, Klaus: 4 articles (06/2011 - 05/2002)|
|3.||Boot, Erik: 3 articles (09/2011 - 01/2011)|
|4.||Booij, Jan: 3 articles (09/2011 - 01/2011)|
|5.||Yang, An-Shoei: 3 articles (11/2009 - 01/2008)|
|6.||Sabri, Osama: 3 articles (08/2008 - 02/2003)|
|7.||Hesse, Swen: 3 articles (08/2008 - 02/2003)|
|8.||Schwarz, Johannes: 3 articles (07/2008 - 05/2002)|
|9.||Meyer, P T: 2 articles (06/2014 - 01/2010)|
|10.||Winz, Oliver H: 2 articles (09/2012 - 08/2008)|
|1.||Parkinsonian Disorders (Parkinsonism)
09/25/2012 - "[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism."
01/01/2005 - "Assessment of post-synaptic D2 receptors with 123I-IBZM SPECT is helpful in distinguishing idiopathic (IPS) from other parkinsonian syndromes (non-IPS). "
07/01/2004 - "[Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients]."
12/01/1993 - "Clinical 123I-IBZM SPECT studies were performed on 15 healthy volunteers and on 28 patients with parkinsonian syndrome. "
01/01/2010 - "IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement."
|2.||Parkinson Disease (Parkinson's Disease)
07/01/2005 - "123I-IBZM SPECT is an effective diagnostic tool in the establishment of the differential diagnosis in patients with Parkinson's disease and Parkinson-Plus. "
01/01/1998 - "The results of IBZM-SPECT were compared with the long-term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs incompatible with Parkinson's disease (PD). "
07/01/1996 - "We prospectively studied the effect of dopaminomimetic treatment on specific [123I]IBZM binding measured by SPECT in 29 patients with a clinical diagnosis of Parkinson's disease, none of whom had previously received dopaminomimetic drugs. "
07/01/1995 - "Twelve patients with asymmetric clinical signs of idiopathic Parkinson's disease were injected with a bolus of [123I]IBZM, and multiple SPECT scans recorded the time course of radioligand uptake. "
03/01/1993 - "The striatal D2 receptor was investigated for variability of behavior in 16 patients with Parkinson disease by means of SPECT using 123I-IBZM, a recently synthesized radioligand with high affinity and specificity for this type of receptor. "
|3.||Neuroleptic Malignant Syndrome
|4.||Schizophrenia (Dementia Praecox)
09/01/1998 - "Forty-four inpatients with schizophrenia, including 12 patients with schizodominant schizoaffective disorder, were evaluated using 123I-iodobenzamide (IBZM) and single photon emission computed tomography. "
09/01/1999 - "The aim of this study was to test, using single photon emission computed tomography (SPECT) and [(123)I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. "
05/01/2012 - "Upon amphetamine challenge, mean IBZM binding decreased by about 4.9 ± 7.6% in controls (n=7) compared to a mean of 12.4 ± 5.8% in subjects with schizophrenia (p<0.05). "
05/15/2004 - "The reduction in [123I]IBZM V(3)" induced by amphetamine in SPD was similar to that observed in remitted schizophrenia patients (-10 +/- 9%, n = 17), but significantly lower than that observed during illness exacerbation (-24 +/- 13%, n = 17). "
11/25/1996 - "Seventeen psychiatric patients (11 with schizophrenia, 5 with other psychotic disorders, and 1 with obsessive-compulsive disorder) were examined by single photon emission computed tomography with 123I-iodobenzamide (IBZM) as tracer. "
|5.||Pituitary Neoplasms (Pituitary Adenoma)
01/01/1994 - "IBZM-binding in the striatum was found to be significantly lower in the group of pituitary tumor patients as compared to controls. "
12/01/1996 - "Scintigraphy using 123I-IBZM was performed in 5 patients with PRL-secreting macroadenomas, 2 patients with PRL-secreting microadenomas, 17 patients with clinically non-functioning pituitary adenomas (NFPAs), 12 patients with GH-secreting adenomas and 1 patient with a TSH-secreting macroadenoma. "
08/01/1999 - "Our results suggest that both suppression tests with OCT and BCR, and scintigraphic studies in vivo with 123I-IBZM and 111In-OCT can be predictive for the effectiveness of therapies with dopamine agonists and/or SS-analogs in patients with mixed PRL/GH-secreting pituitary tumors. "
01/01/1994 - "Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors."
08/01/1995 - "In the other patient, a 27-yr-old man presenting with cerebrospinal fluid rhinorrhea, basal PRL levels were at 5000 ng/mL; magnetic resonance imaging (MRI) demonstrated a huge pituitary tumor, and SPECT showed a very intense concentration of IBZM at the level of the adenoma. "
|1.||Levodopa (L Dopa)
|2.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|3.||2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropane
|4.||Dopamine Receptors (Dopamine Receptor)
|8.||Dopamine Agonists (Dopamine Agonist)
|10.||RTI 55 (Iometopane)
|1.||Gamma Cameras (Gamma Camera)